# Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia

> **NCT02532218** · PHASE2 · UNKNOWN · sponsor: **Arisaph Pharmaceuticals Inc** · enrollment: 176 (estimated)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** ARI-3037MO

## Key facts

- **NCT ID:** NCT02532218
- **Lead sponsor:** Arisaph Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2016-09
- **Final completion:** 2016-12
- **Target enrollment:** 176 (ESTIMATED)
- **Last updated:** 2016-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02532218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02532218, "Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02532218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*